According to a recent study, combination therapy with site-specific salicylic acid and retinol demonstrated significant clinical improvement in acne and post-inflammatory hyperpigmentation (PIH).
PsO patients trust topicals less than AD patients
According to a recent study, trust levels regarding topical therapy were higher among atopic dermatitis (AD) patients than psoriasis (PsO) patients.
Text message intervention effective in improving cardiovascular risk in PsO patients
According to a recent study, a text message intervention system improved cardiovascular risk behaviours and patient confidence managing their health in adult psoriasis patients.
AD associated with increased risk of retinal detachment
According to a recent study, patients with atopic dermatitis (AD) have an increased risk of retinal detachment and postoperative proliferative vitreoretinopathy (PVR).
Researchers develop intelligent tattoo to detect melanoma
Researchers have developed a minimally invasive ‘intelligent tattoo’ for the early detection of melanoma or micro-melanoma.
Concomitant ixekizumab, tirzepatide improves skin clearance, reduces weight in PsO patients
According to a recent study, concomitant ixekizumab and tirzepatide improved skin clearance and reductions in weight in patients with moderate-to-severe psoriasis.
Risankizumab linked to lower risk of serious infection than other systemic treatments
According to a recent study, risankizumab was associated with a lower risk of serious infections when compared to other systemic treatments for psoriasis.
Study shows sensitive skin syndrome is biologically different from rosacea
According to a recent study, sensitive skin syndrome is biologically distinct from rosacea and may require more targeted treatment.
Teen perceptions of sun protection, tanning linked to cancer risk behaviours
According to a recent study, how high school students perceive the costs of sun protection and rewards of tanning significantly affect sun-safe behaviours.
Melanoma immune cell composition may predict benefit from combination immunotherapy
According to a recent study, the tumour immune cell environment may determine whether or not a melanoma patient will respond to combination immunotherapy.
HealthMinute.TV 